Tilray Brands, Inc. - Common Stock (TLRY)

Tilray reveals new study on THC:CBD absorption while expanding brand efforts with a Montauk-Faherty beachside collaboration.

Tilray shares rise as it becomes first to launch branded medical cannabis in Italy.

The 3 analysts that cover Tilray Brands stock have a consensus rating of

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a high-risk, high-reward environment due to the lack of reliable analyst price targets.

A reverse stock split is when a company reduces the number of its outstanding shares which increases the price per share, and is often used to boost a company’s stock price to meet exchange listing requirements or improve its market perception.

Tilray Brands share price crashed to a record low this year.

A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.

Tilray is building a new adult beverage category with hemp THC drinks, as alcohol declines and competition from Big Tobacco heats up.

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the beverages, alcohol, and tobacco industry, including Tilray (NASDAQ:TLRY) and its peers.

Germany became the world's top importer of medical cannabis, but political pressure could challenge telehealth-driven growth.

Cannabis news of the week: Texas targets hemp, DEA blames legal states, Argentina revamps REPROCANN, and Tilray expands in Europe.

Tilray's medical arm expands into Germany with launch of Good Supply brand, offering affordable and high-quality cannabis flower. TLRY stock up 2.33%

Tilray shares trade flat as company expands cannabis lineup with XMG Atomic Sours drinks and gummies.